0000000000116082

AUTHOR

Tabassome Simon

0000-0002-4550-0450

showing 32 related works from this author

Five-Year Survival in Patients With ST-Segment–Elevation Myocardial Infarction According to Modalities of Reperfusion Therapy

2014

Background— Although primary percutaneous coronary intervention (pPCI) is the preferred reperfusion method for ST-segment–elevation myocardial infarction, it remains difficult to implement in many areas, and fibrinolytic therapy is still widely used. Methods and Results— We assessed 5-year mortality in patients with ST-segment–elevation myocardial infarction from the French Registry of Acute ST-Elevation or Non-ST Elevation Myocardial Infarction (FAST-MI) 2005 according to use and type of reperfusion therapy. Of 1492 patients with ST-segment–elevation myocardial infarction with a first call ≤12 hours from onset, 447 (30%) received fibrinolysis (66% prehospital; 97% with subsequent angiogra…

Malemedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionMyocardial Reperfusion030204 cardiovascular system & hematologyCohort Studies03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineReperfusion therapyFibrinolytic AgentsPhysiology (medical)Internal medicineFibrinolysisHumansMedicineST segmentRegistries030212 general & internal medicineMyocardial infarctionAgedAged 80 and overbusiness.industryST elevationHazard ratioPercutaneous coronary interventionMiddle Agedmedicine.disease3. Good healthSurgerySurvival RateTreatment OutcomeConventional PCICardiologyFemaleFranceCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.

2013

International audience; OBJECTIVE: To explore the risk of new or recurrent cancer among patients with IBD and previous cancer, exposed or not to immunosuppressants. DESIGN: Among the 17 047 patients of the CESAME prospective observational cohort who were enrolled from May 2004 to June 2005, and followed-up until December 2007, we identified 405 patients with cancer diagnosed previous to study entry. We calculated the rates of incident cancer in patients with or without previous cancer, and we assessed by survival analysis and nested case-control study the impact of immunosuppressants on the risk of incident new or recurrent cancer in patients with previous cancer. RESULTS: The rate of incid…

OncologyAdultMalemedicine.medical_specialtyAzathioprineKaplan-Meier EstimateCrohn Disease[ CHIM.ORGA ] Chemical Sciences/Organic chemistryRisk FactorsInternal medicineNeoplasmsEpidemiology of cancermedicineHumansProspective StudiesSurvival analysisAgedProportional Hazards ModelsCrohn's diseasebusiness.industry[CHIM.ORGA]Chemical Sciences/Organic chemistryIncidence (epidemiology)IncidenceGastroenterologyCancerMiddle Agedmedicine.diseaseUlcerative colitis3. Good healthSurgeryCase-Control StudiesCohortMultivariate AnalysisColitis UlcerativeFemaleNeoplasm Recurrence LocalbusinessImmunosuppressive Agentsmedicine.drugFollow-Up Studies
researchProduct

Hospital Admissions for Acute Myocardial Infarction Before and After Lockdown According to Regional Prevalence of COVID-19 and Patient Profile

2020

Aim: to evaluate the impact of a nationwide lockdown in France on acute myocardial infarction (AMI) admissions, by patient characteristics and regional prevalence of the pandemic. Methods and Results: We collected data from 21 centres participating in the on-going FRENCHIE registry (NCT04050956), which collects data from all patients admitted for STEMI or NSTEMI within 48 hours of symptom onset. We compared weekly admissions in the 4 weeks preceding and the 4 weeks following institution of the lockdown. We observed a brutal 30% decrease in AMI admissions (24% for STEMI and 36% for NSTEMI, P=0.14) following institution of the lockdown, with similar trends according to gender (30% decrease in…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industryFamily medicineHospital admissionmedicinePatient profilePatient characteristicsIn patientSymptom onsetbusinessRegulatory authoritySSRN Electronic Journal
researchProduct

Diuretic vs. placebo in intermediate-risk acute pulmonary embolism: a randomized clinical trial

2022

Abstract Aims The role of diuretics in patients with intermediate-risk pulmonary embolism (PE) is controversial. In this multicentre, double-blind trial, we randomly assigned normotensive patients with intermediate-risk PE to receive either a single 80 mg bolus of furosemide or a placebo. Methods and results Eligible patients had at least a simplified PE Severity Index (sPESI) ≥1 with right ventricular dysfunction. The primary efficacy endpoint assessed 24 h after randomization included (i) absence of oligo-anuria and (ii) normalization of all sPESI items. Safety outcomes were worsening renal function and major adverse outcomes at 48 hours defined by death, cardiac arrest, mechanical ventil…

Randomizationmedicine.medical_treatmentVentricular Dysfunction Right[SDV]Life Sciences [q-bio]Critical Care and Intensive Care MedicinePlacebolaw.inventionRandomized controlled trialDouble-Blind MethodlawFurosemidemedicineHumansDiureticsbusiness.industryFurosemideGeneral Medicinemedicine.diseasePulmonary embolismBlood pressureTreatment OutcomeAnesthesiaAcute DiseaseDiureticBolus (digestion)Cardiology and Cardiovascular MedicinebusinessPulmonary Embolismmedicine.drug
researchProduct

Additional file 6 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

2020

Additional file 6. (A) Sorensen similarity index between donor and recipient fecal microbiota 6 weeks after FMT or sham, separating “FMT” failure from “FMT success”.

fluids and secretions
researchProduct

Risk of Colorectal High-Grade Dysplasia and Cancer in a Prospective Observational Cohort of Patients with Inflammatory Bowel Disease.

2013

International audience; BACKGROUND AND AIMS:: There is an unclear risk of colonic high-grade dysplasia (HGD) and colorectal cancer (CRC) among patients with inflammatory bowel disease (IBD) treated with immunosuppressants. We analyzed data on CRC development among patients with IBD enrolled in the observational cohort Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales En France (CESAME). METHODS:: We followed and collected data from 19,486 patients with IBD (60.3% with Crohn's disease, 30.1% receiving thiopurine therapy) enrolled in CESAME from May 2004 and June 2005, and followed until December 2007. When the study began, 2841 patients (14.6%) were characterized as havin…

AdultMaleRiskmedicine.medical_specialtyColorectal cancerPopulationInflammatory bowel diseaseGastroenterologyPrimary sclerosing cholangitisCohort Studies03 medical and health sciences0302 clinical medicine[ CHIM.ORGA ] Chemical Sciences/Organic chemistryInternal medicinemedicineHumansProspective StudiesProspective cohort studyeducationAged 80 and overeducation.field_of_studyCrohn's diseaseHepatologyThiopurine methyltransferasebiology[CHIM.ORGA]Chemical Sciences/Organic chemistrybusiness.industryIncidenceGastroenterologyMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisdigestive system diseases3. Good health030220 oncology & carcinogenesisMultivariate Analysisbiology.proteinFemale030211 gastroenterology & hepatologyColorectal NeoplasmsbusinessPrecancerous Conditions
researchProduct

Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry)

2017

IF 3.398; International audience; The prognosis of patients with acute myocardial infarction (AMI) has notably improved in the past 20 years. Using the French Registry of ST-Elevation and Non-ST-elevation Myocardial Infarction (FAST-MI) 2010 registry, we investigated whether previous manifestations of atherosclerotic disease (i.e., previous MI, or a history of any form of atherosclerotic disease) are at truly increased risk compared with those in whom AMI is the first manifestation of the disease. FAST-MI 2010 is a nationwide French registry including 3,079 patients with AMI, among whom 1,062 patients had a history of cardiovascular atherosclerotic disease and 498 patients had a history of …

MaleMESH : Atherosclerosismedicine.medical_treatmentMESH : MortalityMyocardial InfarctionMESH : AgedMESH : Prospective StudiesAngiotensin-Converting Enzyme InhibitorsCoronary Artery DiseaseDiseaseMESH : Cerebrovascular Disorders0302 clinical medicineMedicineLongitudinal StudiesProspective StudiesMESH: Coronary Artery DiseaseMyocardial infarctionCoronary Artery BypassMESH: Treatment OutcomeCause of deathAged 80 and overeducation.field_of_studyMESH: Middle AgedHazard ratioMESH : Platelet Aggregation InhibitorsPrognosisMESH: Case-Control Studies3. Good healthMESH: Myocardial InfarctionMESH: Angiotensin Receptor AntagonistsMESH : Angiotensin-Converting Enzyme InhibitorsCardiology and Cardiovascular MedicineMESH: Percutaneous Coronary InterventionMESH : Case-Control Studiesmedicine.medical_specialtyMESH : Angiotensin Receptor AntagonistsMESH: Prognosis03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedMESH : Coronary Artery DiseaseMESH : Aged 80 and overMESH: Hydroxymethylglutaryl-CoA Reductase InhibitorseducationMESH: Age DistributionAgedMESH: HumansMESH: MortalityProportional hazards modelMESH: Coronary Artery BypassMESH : HumansCase-control studyMESH : Proportional Hazards Modelsmedicine.diseaseMESH : Coronary Artery BypassCase-Control StudiesMESH: FemaleMESH: RegistriesMESH : Age Distribution030204 cardiovascular system & hematologyMESH: AtherosclerosisMESH: Proportional Hazards ModelsMESH: Cause of DeathMESH: Aged 80 and overMESH : Percutaneous Coronary InterventionRisk FactorsMESH: Risk FactorsCause of DeathMESH : FemaleRegistries030212 general & internal medicineMESH: Longitudinal StudiesMESH : Longitudinal StudiesMESH: AgedMESH : PrognosisMESH: Angiotensin-Converting Enzyme InhibitorsMESH: Adrenergic beta-AntagonistsMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsTreatment OutcomeMESH: Platelet Aggregation InhibitorsCardiologyFemaleMESH: Cerebrovascular DisordersFranceMESH : MaleAdrenergic beta-AntagonistsMESH : Adrenergic beta-AntagonistsPopulationMESH : Treatment OutcomeMESH: Multivariate AnalysisAngiotensin Receptor AntagonistsAge DistributionInternal medicineMortalityMESH : FranceProportional Hazards ModelsMESH : Cause of Deathbusiness.industryMESH : Hydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Multivariate AnalysisPercutaneous coronary interventionAtherosclerosisMESH: MaleMESH: Prospective StudiesMESH: FranceCerebrovascular DisordersMultivariate AnalysisHydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Myocardial InfarctionbusinessPlatelet Aggregation InhibitorsMESH : RegistriesThe American Journal of Cardiology
researchProduct

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

2012

International audience; BACKGROUND: It remains to be shown whether inflammatory bowel disease (IBD) is associated with an increased risk of primary intestinal lymphoproliferative disorders (PILD). We assessed this risk in the CESAME French nationwide prospective observational cohort. METHODS: In all, 680 gastroenterologists enrolled 19,486 patients with IBD (Crohn's disease in 60.3%) from May 2004 to June 2005. Follow-up ended on 31 December 2007. Available biopsy samples and surgical specimens from patients with PILD (n = 14) were centralized for review. The reference incidence of PILD in the general population was obtained from the Côte d'Or registry and was used as a comparator to assess…

AdultMalemedicine.medical_specialtyPopulationGastroenterologyInflammatory bowel diseaseYoung Adult03 medical and health sciences0302 clinical medicineCrohn DiseaseInterquartile range[ CHIM.ORGA ] Chemical Sciences/Organic chemistryInternal medicineAzathioprinemedicineHumansImmunology and AllergyProspective StudiesChildeducationAgedAged 80 and overeducation.field_of_studyCrohn's diseaseThiopurine methyltransferasebiologyMercaptopurinebusiness.industry[CHIM.ORGA]Chemical Sciences/Organic chemistryIncidenceIncidence (epidemiology)GastroenterologyCase-control studyOdds ratioMiddle Agedmedicine.diseaseLymphoproliferative Disorders3. Good healthTreatment OutcomeCase-Control Studies030220 oncology & carcinogenesisbiology.proteinColitis UlcerativeFemale030211 gastroenterology & hepatologyFrancebusinessImmunosuppressive AgentsFollow-Up Studies
researchProduct

Additional file 10 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

2020

Additional file 10. Clinical efficacy of FMT is associated with colonization by the donor microbiota. Flare-free survival of patients in the FMT and the Sham groups.

researchProduct

Long-term outcomes after acute myocardial infarction in patients with familial hypercholesterolemia: The French registry of Acute ST-elevation and no…

2020

Patients with familial hypercholesterolemia (FH) are prone to develop acute myocardial infarction (AMI) at a younger age.The aim of the present study was to assess 5-year outcomes after AMI according to the presence of FH in a large multicenter cohort of patients.The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction consists of nationwide surveys recruiting patients over a 1- to 2-month period every 5 years. Patients recruited in 2005 and 2010 were followed up to 5 years.Of 5147 patients discharged alive and in whom FH status could be assessed, 2.8% had probable/definite FH, using an adapted Dutch Lipid Clinic score. They were 12 years younger, on average, tha…

Malemedicine.medical_specialty[SDV]Life Sciences [q-bio]Endocrinology Diabetes and MetabolismFamilial hypercholesterolemia030204 cardiovascular system & hematologyCohort StudiesHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineSurveys and QuestionnairesInternal MedicinemedicineHumansIn patient030212 general & internal medicineMyocardial infarctionRegistriesNon-ST Elevated Myocardial InfarctionStrokeComputingMilieux_MISCELLANEOUSAgedNutrition and Dieteticsbusiness.industryST elevationHazard ratioMiddle Agedmedicine.diseasePrognosisConfidence interval3. Good healthCohortST Elevation Myocardial Infarction[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFemaleFranceHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessJournal of clinical lipidology
researchProduct

The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.

2019

International audience; Background: The COMPASS trial assessed the impact of adding low dose rivaroxaban to aspirin in selected patients (pts). After an acute myocardial infarction (MI), when dual antiplatelet treatment is no longer needed, patients might be eligible for aspirin/rivaroxaban co-therapy. The characteristics and risks of such a population are unclear.Methods: Data were extracted from the FAST-MI 2005, 2010 and 2015 nationwide French registries. Characteristics and long-term mortality were compared according to COMPASS eligibility and between registry and trial populations.Results: Among 9954 patients alive and free of events at one year, 4402 (44%) were classified as COMPASS-L…

Malemedicine.medical_specialtyanimal structuresPopulationMyocardial Infarction030204 cardiovascular system & hematologyCoronary artery diseaselaw.inventionCoronary artery diseaseCohort Studies03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRandomized controlled trialRivaroxabanlawCompassInternal medicinemedicineHumans030212 general & internal medicineMyocardial infarctionRegistrieseducationAgedAged 80 and overIschemic and hemorrhagic riskAspirinRivaroxabaneducation.field_of_studyAspirinbusiness.industryAnticoagulantsMiddle Agedmedicine.disease[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthIncreased risk[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyPopulation SurveillanceCOMPASS study[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyFemaleFranceCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugFollow-Up StudiesInternational journal of cardiology
researchProduct

Additional file 9 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

2020

Additional file 9. Evolution of similarity index (1-unweighted Unifrac) between donor and recipient fecal microbiota in patients with FMT success and FMT failure.

fluids and secretions
researchProduct

Chronic Kidney Disease, Diabetes, and Risk of Mortality After Acute Myocardial Infarction: Insight From the FAST-MI Program

2020

Diabetes is associated with a substantially increased risk of all-cause death, mainly driven by cardiovascular (CV) mortality. Furthermore, diabetes is associated with poorer outcomes after acute myocardial infarction (AMI) (1). Impaired glomerular filtration rate (GFR) is also associated with an increased risk of CV mortality (2). However, whether diabetes still confers a higher risk of mortality in patients with impaired GFR remains unknown. The aim of this study was to assess the long-term prognostic significance of both diabetes and renal impairment in two prospective nationwide cohorts of AMI patients: FAST-MI (French Registry of Acute ST-Elevation or non-ST-elevation Myocardial Infarc…

medicine.medical_specialtyEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Renal function030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusIntensive careInternal MedicinemedicineRisk of mortality030212 general & internal medicineMyocardial infarction10. No inequalityComputingMilieux_MISCELLANEOUSAdvanced and Specialized NursingFramingham Risk Scorebusiness.industrymedicine.disease3. Good healthHeart failureCardiologybusinessKidney disease
researchProduct

Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

2020

Abstract Background The role of the gut microbiota in Crohn’s disease (CD) is established and fecal microbiota transplantation (FMT) is an attractive therapeutic strategy. No randomized controlled clinical trial results are available. We performed a randomized, single-blind, sham-controlled pilot trial of FMT in adults with colonic or ileo-colonic CD. Method Patients enrolled while in flare received oral corticosteroid. Once in clinical remission, patients were randomized to receive either FMT or sham transplantation during a colonoscopy. Corticosteroids were tapered and a second colonoscopy was performed at week 6. The primary endpoint was the implantation of the donor microbiota at week 6…

Microbiology (medical)AdultMaleCrohn’s diseasemedicine.medical_specialtymedicine.drug_class[SDV]Life Sciences [q-bio]ColonoscopyPilot ProjectsGut floraMicrobiologyGastroenterologySeverity of Illness Indexlcsh:Microbial ecologylaw.inventionFecal microbiota transplantation03 medical and health sciencesFeces0302 clinical medicineRandomized controlled trialCrohn DiseaselawAdrenal Cortex HormonesInternal medicinemedicineClinical endpointHumansSingle-Blind Method030304 developmental biology0303 health sciencesCrohn's diseasebiologymedicine.diagnostic_testMicrobiotaResearchRemission Inductionbiology.organism_classificationmedicine.disease3. Good healthClinical trialTransplantationCrohn's diseaseTreatment OutcomeResearch DesignRandomized controlled trialCorticosteroidlcsh:QR100-130030211 gastroenterology & hepatologyFemaleMicrobiome
researchProduct

Do randomized clinical trial selection criteria reflect levels of risk as observed in a general population of acute myocardial infarction survivors? …

2016

IF 4.638; International audience; Background: Few clinical trials have focused on populations with a history of distant myocardial infarction (MI). The PEGASUS trial assessed the impact of dual antiplatelet therapy in such patients, selected by enrichment criteria of high cardiovascular risk. Whether the PEGASUS population reflects the risk of a broader post-MI population is questionable. We analyzed whether 4-year mortality of a routine-practice population would differ according to the inclusion and exclusion criteria used in PEGASUS.Methods: FAST-MI is a nationwide French registry recruiting acute MI patients in November 2005; 2490 patients alive and without recurrent MI at one year were …

MaleTicagrelorMyocardial Infarction030204 cardiovascular system & hematologyCoronary artery diseaselaw.inventionCoronary artery disease0302 clinical medicineRandomized controlled trialRisk FactorslawSecondary PreventionRegistriesSurvivors030212 general & internal medicineMyocardial infarctionRandomized Controlled Trials as TopicAged 80 and overeducation.field_of_studyReperfusion therapyEvidence-Based PharmacotherapyMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemST-elevation myocardial infarctionPopulation SurveillanceInclusion and exclusion criteriaFemaleFranceAtherothrombotic EventsCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyPopulationAcute St-ElevationAcute myocardial infarctionVorapaxar03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansMortalityeducationSelection (genetic algorithm)AgedAspirinbusiness.industryPatient SelectionAntiplatelet therapymedicine.diseaseComorbidityClinical trialAdherencePhysical therapyTherapybusinessFollow-Up Studies
researchProduct

Additional file 2 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

2020

Additional file 2. Screening measures for donors.

researchProduct

Additional file 5 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

2020

Additional file 5. Change in clinical and biological parameters between day 0 and week 6 for FMT and sham treatment groups.

sense organsskin and connective tissue diseases
researchProduct

Cardiac rehabilitation and 5-year mortality after acute coronary syndromes: The 2005 French FAST-MI study.

2016

IF 2.271; International audience; Background. - Clinical studies have shown a beneficial effect of cardiac rehabilitation (CR) on mortality.Objective. - To study the effect of CR prescription at discharge on 5-year mortality in patients with acute myocardial infarction (AMI).Methods. - Participants, from the 2005 French FAST-MI hospital registry, were 2894 survivors at discharge, divided according to AMI type: ST-segment elevation myocardial infarction (STEMI; n=1523) and non-STEMI (NSTEMI; n=1371). The effect of CR prescription on mortality was analysed using a Cox proportional hazards model.Results. - At discharge, 22.1% of patients had a CR prescription. Patients referred to CR were youn…

MaleMESH: Chi-Square Distributionmedicine.medical_treatmentMESH : Acute Coronary SyndromeMyocardial InfarctionMESH : AgedMESH : Prospective StudiesCardiac rehabilitationMESH: Risk Assessment0302 clinical medicineMyocardial infarctionProspective StudiesReferral and ConsultationMESH: Treatment OutcomeRehabilitationMESH: Middle AgedGeneral MedicineMESH: Follow-Up Studies3. Good healthMESH: Myocardial InfarctionMESH : Patient DischargeCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute myocardial infarctionMortalitéRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedAcute Coronary SyndromeMESH: Kaplan-Meier EstimateAgedChi-Square DistributionMESH: HumansMESH : Chi-Square DistributionProportional hazards modelMESH: Patient DischargeMESH : HumansPatient survivalMESH : Follow-Up Studiesmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Acute Coronary SyndromeST-segment elevation myocardial infarctionMESH: FemaleTime FactorsMESH: RegistriesKaplan-Meier Estimate030204 cardiovascular system & hematologyMESH : Referral and ConsultationMESH: Proportional Hazards ModelsOlder patientsRisk FactorsMESH: Risk FactorsMESH : Female030212 general & internal medicineRegistriesMESH : Risk AssessmentMESH: AgedEjection fractionNon–ST-segment elevation myocardial infarctionMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsPatient DischargeTreatment OutcomeFemaleFranceMESH : Time FactorsMESH : MaleMESH : Treatment OutcomeMESH: Multivariate AnalysisMESH : Kaplan-Meier EstimateMESH: Referral and ConsultationInternal medicineInfarctus du myocarde sans sus-décalage du segment STmedicineIn patientcardiovascular diseasesMedical prescriptionMortalityRéadaptation cardiaqueMESH : FranceProportional Hazards Modelsbusiness.industryInfarctus du myocarde avec sus-décalage du segment STMESH: Time FactorsMESH : Multivariate AnalysisMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceInfarctus du myocarde aiguMultivariate AnalysisMESH : Myocardial InfarctionbusinessMESH : RegistriesFollow-Up Studies
researchProduct

Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in Fra…

2020

Background The COVID-19 pandemic has had a profound effect on general health care. We aimed to evaluate the effect of a nationwide lockdown in France on admissions to hospital for acute myocardial infarction, by patient characteristics and regional prevalence of the pandemic. Methods In this registry study, we collected data from 21 centres participating in the ongoing French Cohort of Myocardial Infarction Evaluation (FRENCHIE) registry, which collects data from all patients admitted for ST segment elevation myocardial infarction (STEMI) or non-ST segment elevation myocardial infarction (NSTEMI) within 48 h of symptom onset. We analysed weekly hospital admissions over 8 weeks: the 4 weeks …

Malemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Pneumonia ViralMyocardial InfarctionRate ratio01 natural sciencesCohort Studies03 medical and health sciencessymbols.namesake0302 clinical medicinePatient Admission[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRisk FactorsPrevalenceMedicineST segmentHumans030212 general & internal medicinePoisson regressionMyocardial infarctionRegistries0101 mathematicsPandemicsAgedAged 80 and overbusiness.industry010102 general mathematicsPublic Health Environmental and Occupational HealthCOVID-19ArticlesMiddle Agedmedicine.disease3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieEmergency medicineCohortsymbolsObservational studyFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFrancebusinessCoronavirus InfectionsCohort study
researchProduct

0132: Identifying familial hypercholesterolemia from registries of patients with acute myocardial infarction: an algorithm-based approach

2016

Background and aims Familial hypercholesterolemia (FH) is at very high risk of early myocardial infarction (MI). The prevalence of FH, which is estimated to be at least 1:500 in the general population, remains unclear in patients with acute MI. From databases of 2 French regional and nationwide registries of acute MI (RICO and FAST-MI, respectively), we aimed to determine FH prevalence by developing a specific algorithm. Methods and results Consecutive patients with AMI ≤48 hours of onset included 1) in FAST-MI: during a one-month period in 213 institutions at the end of 2005 and 2) in RICO: from January 2001 December 2013 (≈13y), were considered in the 2 databases. The algorithm was adapte…

education.field_of_studybusiness.industryVascular diseasePopulationFamilial hypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematology[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.disease03 medical and health sciencesMyocardial infarction0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMedicineIn patient030212 general & internal medicineMyocardial infarctionLipid loweringFamily historyCardiology and Cardiovascular MedicinebusinesseducationAlgorithmLipid clinicComputingMilieux_MISCELLANEOUS
researchProduct

Effect of Systematic Intensive Care Unit Triage on Long-term Mortality Among Critically Ill Elderly Patients in France

2017

Importance The high mortality rate in critically ill elderly patients has led to questioning of the beneficial effect of intensive care unit (ICU) admission and to a variable ICU use among this population. Objective To determine whether a recommendation for systematic ICU admission in critically ill elderly patients reduces 6-month mortality compared with usual practice. Design, Setting, and Participants Multicenter, cluster-randomized clinical trial of 3037 critically ill patients aged 75 years or older, free of cancer, with preserved functional status (Index of Independence in Activities of Daily Living ≥4) and nutritional status (absence of cachexia) who arrived at the emergency departme…

MalePediatricsmedicine.medical_specialtyTime FactorsCritical CareCritical IllnessHealth StatusPopulationlaw.invention03 medical and health sciencesPatient Admission0302 clinical medicineQuality of lifeRandomized controlled triallawActivities of Daily LivingOutcome Assessment Health CaremedicineHumansHospital Mortality030212 general & internal medicineCritical Care OutcomeseducationCritical Care OutcomesAgedAged 80 and over2. Zero hungereducation.field_of_studybusiness.industryMortality rate030208 emergency & critical care medicineGeneral MedicineEmergency departmentIntensive care unit3. Good healthIntensive Care UnitsRelative riskQuality of LifeFemaleFranceTriagebusinessProgram EvaluationJAMA
researchProduct

0133 : Identifying familial hypercholesterolemia from registries of patients with acute myocardial infarction: an algorithm-based approach

2016

Background and aim Familial hypercholesterolemia (FH) is at very high risk of early myocardial infarction (MI). The prevalence of FH, which is estimated to be at least 1:500 in the general population, remains unclear in patients with acute MI. From databases of 3 French regional and nationwide registries of acute MI (RICO and FAST-MI 2005 and 2010, respectively), we aimed to determine FH prevalence by developing a specific algorithm. Methods and results Consecutive patients with AMI ≤48 hours of onset included 1) in FAST-MI : during a one-month period in 223 institutions at the end of 2005 and 213 institutions at the end of 2010, and 2) in RICO :from January 2001 – December 2013 (≈ 13 y), w…

Pediatricsmedicine.medical_specialtyPopulationFamilial hypercholesterolemiaFamilial hypercholesterolemiaDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine030212 general & internal medicineMyocardial infarctionFamily historyeducationAcute miComputingMilieux_MISCELLANEOUSeducation.field_of_studybusiness.industryVascular disease[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseMyocardial infarctionbusinessCardiology and Cardiovascular MedicineVery high riskAlgorithmArchives of Cardiovascular Diseases Supplements
researchProduct

Additional file 4 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

2020

Additional file 4. Characteristics of patients at selection (before starting corticosteroids.

hormones hormone substitutes and hormone antagonists
researchProduct

Additional file 1 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

2020

Additional file 1: Study design.

Data_FILES
researchProduct

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

2009

International audience; BACKGROUND: Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a prospective observational cohort study. METHODS: 19,486 patients with inflammatory bowel disease, of whom 11,759 (60.3%) had Crohn's disease and 7727 (39.7%) had ulcerative colitis or unclassified inflammatory bowel disease, were enrolled in a nationwide French cohort by 680 gastroenterologists, who reported details of immunosuppressive therapy during the observation period, cases of cancer, and deaths. The risk of lymphoproliferative disorder was assessed according to thiopurine expos…

MaleTime FactorsMESH : Age DistributionMESH : Prospective StudiesMESH : AgedInflammatory bowel diseaseMESH: Proportional Hazards Models0302 clinical medicineMESH: Lymphoproliferative DisordersCrohn DiseaseRisk FactorsMESH: Risk FactorsMESH : PurinesMESH : FemaleProspective StudiesMESH: IncidenceProspective cohort studyMESH : Immunosuppressive AgentsMESH : Sex DistributionMESH: AgedMESH : Tumor Necrosis Factor-alphaCrohn's diseaseMESH: Middle AgedThiopurine methyltransferasebiologyMESH : Lymphoproliferative DisordersIncidenceMESH: Sex DistributionGeneral MedicineMESH: PurinesMiddle AgedMESH : AdultMESH : Colitis UlcerativeUlcerative colitisMESH : Risk FactorsMESH : Incidence3. Good health030220 oncology & carcinogenesisCohortDrug Therapy CombinationFemale030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFranceMESH: Immunosuppressive AgentsImmunosuppressive AgentsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyMESH : MaleMESH: Colitis UlcerativeLymphoproliferative disordersMESH : Crohn DiseaseMESH: Multivariate Analysis03 medical and health sciencesAge DistributionInternal medicinemedicineHumansMESH : Middle AgedSex DistributionMESH : FranceMESH: Age DistributionAgedProportional Hazards ModelsMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphabusiness.industryMESH : Drug Therapy CombinationMESH: Time FactorsMESH : HumansMESH : Multivariate AnalysisMESH: Adult[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseMESH : Proportional Hazards ModelsLymphoproliferative DisordersMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceMESH: Drug Therapy CombinationPurinesMESH: Tumor Necrosis Factor-alphaMultivariate Analysisbiology.proteinColitis UlcerativebusinessMESH: Female
researchProduct

β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study.

2016

OBJECTIVE To assess the association between early and prolonged beta blocker treatment and mortality after acute myocardial infarction. DESIGN Multicentre prospective cohort study. SETTING Nationwide French registry of Acute ST- and non-STelevation Myocardial Infarction (FAST-MI) (at 223 centres) at the end of 2005. PARTICIPANTS 2679 consecutive patients with acute myocardial infarction and without heart failure or left ventricular dysfunction. MAIN OUTCOME MEASURES Mortality was assessed at 30 days in relation to early use of beta blockers (<= 48 hours of admission), at one year in relation to discharge prescription, and at five years in relation to one year use. RESULTS beta blockers were…

MaleTime FactorsMyocardial Infarction030204 cardiovascular system & hematologyCorrectionsCohort Studies0302 clinical medicineMedicine030212 general & internal medicineMyocardial infarctionProspective StudiesProspective cohort studyHazard ratioGeneral MedicineMiddle AgedMetaanalysisPatient Discharge3. Good healthManagementImpactAcute DiseaseCardiologyFemaleLife Sciences & Biomedicinemedicine.medical_specialtyRegistrySt-Segment-Elevationmedicine.drug_classAdrenergic beta-AntagonistsGuidelines03 medical and health sciencesMedicine General & InternalFast-MiInternal medicineGeneral & Internal Medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyClinical-OutcomesHumansBeta blockerSurvival analysisAgedProportional Hazards ModelsHeart FailureScience & Technologybusiness.industryProportional hazards modelResearchCoronary Care Unitsmedicine.diseaseSurvival AnalysisDiscontinuationLogistic ModelsAdherenceHeart failureTherapybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBMJ (Clinical research ed.)
researchProduct

Additional file 8 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

2020

Additional file 8. Abundance of taxa at the genus/species level during the follow-up period in patients with FMT success (A) and FMT failure (B). Proportion of different OTU from donors in patients with FMT success and FMT failure (C). Only taxa representing &gt; 0.1% of the microbiota were taken into account in the analysis.

researchProduct

Additional file 7 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

2020

Additional file 7. Principal coordinate analysis of Bray–Curtis distance in patients with FMT failure (A) or FMT sucess (B). Each PCoA plot represent the samples from a single patient across the different time points. PC1, PC2 and PC3 represent the top three principal coordinates that captured most of the diversity. The fraction of diversity captured by the coordinate is given as a percentage.

researchProduct

Influence of gender on delays and early mortality in ST-segment elevation myocardial infarction: Insight from the first French Metaregistry, 2005–201…

2018

International audience; Background - Women show greater mortality after acute myocardial infarction. We decided to investigate whether gender affects delays and impacts in-hospital mortality in a large population.Methods and results - We performed a patient-level analysis of 7 French MI registries from different regions from January 2005 to December 2012. All patients with acute STEMI were included within 12 h from symptom onset and a first medical contact with a mobile intensive care unit an emergency department of a hospital with percutaneous coronary intervention facility. Primary study outcomes were STEMI, patient and system, delays. Secondary outcome was in-hospital mortality. 16,733 p…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematologyCoronary AngiographyClinical researchSTEMIElectrocardiography03 medical and health sciencesSex Factors0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRisk FactorsGender issuesmedicineHumansST segmentRegistries030212 general & internal medicineMyocardial infarctionSex DistributionSurvival rateAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryPercutaneous coronary interventionRetrospective cohort studyEmergency departmentMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPrognosismedicine.disease3. Good healthSurvival RateClinical researchEmergency medicineST Elevation Myocardial InfarctionFemale[SDV.IB]Life Sciences [q-bio]/BioengineeringCardiology and Cardiovascular MedicinebusinessElectrocardiographyFollow-Up StudiesInternational Journal of Cardiology
researchProduct

In-hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: Results from the French regi…

2019

Summary Background Cancer and acute myocardial infarction (AMI) have important prognostic consequences. Treatment of some cancers may affect coronary artery disease, myocardial function and/or AMI management. Whether the early and long-term mortality of patients with AMI differ according to their history of cancer remains questionable. Aims To determine in-hospital outcomes and 5-year mortality following AMI according to patient history of cancer. Methods The FAST-MI registry is a nationwide French survey collecting data on characteristics, management and outcomes of 3670 consecutive patients admitted for AMI during October 2005. Results Overall, 246/3664 patients (6.7%) admitted for an AMI…

Malemedicine.medical_specialtyTime Factors[SDV]Life Sciences [q-bio]Infarctus du myocardeAcute myocardial infarction030204 cardiovascular system & hematologyMortalitéRisk AssessmentCoronary artery disease03 medical and health sciences0302 clinical medicineRisk FactorsNeoplasmsInternal medicineMortalité hospitalière.medicineHumansMedical historyHospital MortalityProspective StudiesRegistries030212 general & internal medicineMyocardial infarctioncardiovascular diseasesRisk factorMortalityNon-ST Elevated Myocardial InfarctionAgedCancerAged 80 and overbusiness.industryST elevationHazard ratioGeneral MedicineOdds ratioMiddle Agedmedicine.disease3. Good healthHospitalization[SDV] Life Sciences [q-bio]In-hospital mortalityTreatment OutcomeCohortST Elevation Myocardial InfarctionFemaleFranceCardiology and Cardiovascular Medicinebusiness
researchProduct

Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-…

2019

Abstract Aims ST-segment elevation myocardial infarction (STEMI) guidelines recommend primary percutaneous coronary intervention (pPCI) as the default reperfusion strategy when feasible ≤120 min of diagnostic ECG, and a pharmaco-invasive strategy otherwise. There is, however, a lack of direct evidence to support the guidelines, and in real-world situations, pPCI is often performed beyond recommended timelines. To assess 5-year outcomes according to timing of pPCI (timely vs. late) compared with a pharmaco-invasive strategy (fibrinolysis with referral to PCI centre). Methods and results The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) programme c…

medicine.medical_specialtyPercutaneousmedicine.medical_treatment[SDV]Life Sciences [q-bio]Myocardial InfarctionAcute myocardial infarction030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineReperfusion therapyFibrinolytic Agents[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemFibrinolysismedicineHumansST segment030212 general & internal medicineMyocardial infarctioncardiovascular diseasesTimingPrimary PCIbusiness.industryFibrinolysisHazard ratioPercutaneous coronary interventionmedicine.diseaseLong-term outcome3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV] Life Sciences [q-bio]Treatment OutcomeEmergency medicineConventional PCIST Elevation Myocardial InfarctionCardiology and Cardiovascular Medicinebusiness
researchProduct

Additional file 3 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

2020

Additional file 3. Raw sequence data.

Data_FILES
researchProduct